AUA Guidelines: Diagnosis and Treatment of Infertility in Men
AUA Guidelines: Diagnosis and Treatment of Infertility in Men
Co-Host: Robert E. Brannigan, MD
Outline:
Segment #1 Topic: New Table 1 Reviewing “Common Terms” in Semen Analysis and Update to the WHO Semen Analysis Reference Ranges
Segment #2 Update to the WHO Semen Analysis Reference Ranges
Segment #3 Topic: Y Chromosome Microdeletion Testing Change in Testing Guidance
Segment #4 Topic: Pelvic MRI imaging is an option for men with suspected ejaculatory duct obstruction
Segment #5 Topic: For couples with recurrent pregnancy loss, clinicians should evaluate the male partner with karyotype (Expert Opinion) and sperm DNA fragmentation
Diagnosis and Treatment of Infertility in Men: AUA/ASRM Guideline
Brannigan RE, Hermanson L, Kaczmarek J, Kim SK, Kirkby E, Tanrikut C. Updates to male infertility: AUA/ASRM guideline (2024). J Urol. Published online August 15, 2024. doi:10.1097/JU.0000000000004180. https://www.auajournals.org/doi/10.1097/JU.0000000000004180
--------
38:08
AUA Guidelines: Diagnosis And Treatment Of Idiopathic Overactive Bladder
AUA Guidelines: Diagnosis And Treatment Of Idiopathic Overactive Bladder
Co-Host: Anne Pelletier Cameron, MD, FRCSC, URPS
Segment #1: Is this an update to the prior Guideline?
Segment #2: What is new in the Diagnosis, ntitial Assessment and Initial Management of OAB?
Segment#3: What does the Guideline say about Oral Medication?
Segment #4: What's new in minimally invasive prodcedures
Segment #5: UDS and Cystoscopy
Segment #6: What is new and exciting on the horizion for OAB
Segment #7: Where to start and the most impactpact research in this area
The AUA/SUFU Guideline on the Diagnosis and Treatment of Idiopathic Overactive Bladder
Cameron AP, Chung DE, Dielubanza EJ, et al. The AUA/SUFU guideline on the diagnosis and treatment of idiopathic overactive bladder. J Urol. Published online April 23, 2024. doi:10.1097/JU.0000000000003985. https://www.auajournals.org/doi/10.1097/JU.0000000000003985
--------
42:30
AUA Guidelines: Treatment Of Non - Metastatic Muscle - Invasive Bladder Cancer
AUA Guidelines: Treatment Of Non - Metastatic Muscle - Invasive Bladder Cancer
Guest: Jeffrey M Holzbeierlein, MD
Outline:
Segment #1: Guideline Statement 9-Patients who have not received cisplatin-based NAC and have pT3-4 and/or N= disease at cystectomy should receive adjuvant cisplatin based chemotherapy or adjuvant immunotherapy.
Segment #2: Guideline Statement 11-When performing a cystectomy in males the bladder, prostate cand seminal vesicles should be removed (no change) but in females clinicians should consider removal of adjacent reproductive organs based on individual disease characteristics and need to obtain negative margins. Organ sparing procedures in females should be considered based on disease location and characteristics on an individual basis.
Segment #3: Guideline Statement 20-When performing bilateral pelvic lymphadenectomy , clinicians should remove, at a minimum, the external and internal iliac and obturator lymph nodes (standard lymphadenectomy).
Segment #4: Future Directions
Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline
Holzbeierlein J, Bixler BR, Buckley DI, et al. Treatment of non-metastatic muscle-invasive bladder cancer: AUA/ASCO/SUO guideline (2017; amended 2020, 2024). J Urol. Published online April 25, 2024. doi:10.1097/JU.0000000000003981 https://www.auajournals.org/doi/10.1097/JU.0000000000003981
--------
35:22
Biomarkers and Molecular Imaging for Prostate Cancer (Republished)
Biomarkers and Molecular Imaging for Prostate Cancer
CME Available: auau.auanet.org/node/41727
ACKNOWLEDGEMENTS:
Support provided by independent educational grants from:
Lantheus Medical Imaging
Novartis Pharmaceuticals Corporation
LEARNING OBJECTIVES:
At the conclusion of this activity, participants will be able to:
1. Explain the principles of molecular imaging and its application in prostate cancer, including techniques such as PET, MRI, and novel radiotracers.
2. Evaluate recent advances in molecular imaging technologies and their role in improving the accuracy of prostate cancer diagnosis, staging, and treatment monitoring.
3. Define and classify different types of biomarkers relevant to prostate cancer, including diagnostic, prognostic, and predictive biomarkers.
--------
33:29
Appropriate Use of Genetic Testing (Republished)
Appropriate Use of Genetic Testing (who, what, when and how?)
CME Available: auau.auanet.org/node/41734
ACKNOWLEDGEMENTS:
Support provided by independent educational grants from:
Lantheus Medical Imaging
Novartis Pharmaceuticals Corporation
LEARNING OBJECTIVES:
At the conclusion of this activity, participants will be able to:
1. Identify the patient populations that should be considered for genetic testing in prostate cancer, based on family history, personal risk factors, and clinical indications.
2. Integrate genetic testing into clinical practice for prostate cancer, including developing workflows, referral processes, and multidisciplinary collaboration.
3. Utilize genetic test results to inform personalized treatment plans for prostate cancer patients, including targeted therapies and risk reducing strategies.
Brasil